A detailed history of Group One Trading, L.P. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 22,559 shares of ATNM stock, worth $166,936. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,559
Previous 5,040 347.6%
Holding current value
$166,936
Previous $25,000 604.0%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$5.0 - $9.2 $87,595 - $161,174
17,519 Added 347.6%
22,559 $176,000
Q4 2023

Feb 14, 2024

BUY
$4.02 - $6.08 $20,260 - $30,643
5,040 New
5,040 $25,000
Q2 2023

Aug 09, 2023

SELL
$7.15 - $9.39 $173,430 - $227,763
-24,256 Reduced 61.15%
15,413 $114,000
Q1 2023

May 12, 2023

BUY
$8.51 - $14.26 $320,461 - $536,988
37,657 Added 1871.62%
39,669 $374,000
Q4 2022

Feb 09, 2023

SELL
$9.71 - $12.51 $682,069 - $878,752
-70,244 Reduced 97.22%
2,012 $21,000
Q3 2022

Nov 09, 2022

BUY
$4.81 - $8.48 $133,645 - $235,616
27,785 Added 62.48%
72,256 $533,000
Q2 2022

Aug 11, 2022

BUY
$4.71 - $7.11 $150,079 - $226,553
31,864 Added 252.75%
44,471 $214,000
Q1 2022

May 12, 2022

BUY
$4.57 - $6.4 $52,756 - $73,881
11,544 Added 1085.98%
12,607 $64,000
Q4 2021

Feb 11, 2022

BUY
$6.01 - $8.8 $6,388 - $9,354
1,063 New
1,063 $6,000
Q2 2021

Aug 10, 2021

SELL
$7.01 - $8.63 $30,738 - $37,842
-4,385 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$7.62 - $9.79 $212,437 - $272,935
-27,879 Reduced 86.41%
4,385 $33,000
Q4 2020

Feb 10, 2021

BUY
$7.8 - $12.64 $230,513 - $373,549
29,553 Added 1090.11%
32,264 $252,000
Q3 2020

Nov 12, 2020

BUY
$7.26 - $18.0 $19,681 - $48,798
2,711 New
2,711 $26,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $186M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.